For Research Use Only
GLP-2 TRZ
GLP-2 T — research-grade peptide. ≥ 99% purity (HPLC), Certificate of Analysis with every batch. For laboratory research use only.
+ 1 Free 3ml BAC Water
+ 2 Free 3ml BAC Water
10 VIALS · 40% OFF
FREE- 3 Free 3ml BAC Water
- Free GLP-3 R 10mg vial
- Free Priority Shipping
Transparency
Certificate of Analysis
Every batch independently verified by third-party laboratories.
GLP-2 TRZ COA
All Banger Labs products are independently tested by accredited third-party laboratories. Results are batch-specific and provided for research transparency only. This product is not approved for human use.
Lab Verified
Every Dose, Independently Tested
Verified by Vanguard Laboratory — always ≥99.5% purity, tested 7×. Swipe to view your selected dose.
Support
Frequently Asked Questions
Everything you need to know about this product and your order.
Research Overview Cited research summary, handling & references — tap to expand
GLP-2 TRZ: A Research Compendium
What GLP-2 TRZ Is
GLP-2 TRZ (research designation LY3298176) is a synthetic, single-molecule peptide engineered to act as a dual agonist at two incretin receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. The discovery literature describes it as a fatty-acid-modified, 39-amino-acid peptide built on a GIP-based backbone with an albumin-binding side chain, designed to engage both receptors from one molecule.[1] In receptor-pharmacology studies it is characterised as a biased and imbalanced agonist, meaning it activates the two receptors and their downstream signalling pathways to differing degrees, a property that has made it a focus of mechanistic research.[2] Banger Labs supplies GLP-2 TRZ solely as a research chemical for in-vitro and laboratory investigation; it is not a drug, supplement, or product for human or veterinary use.
Areas Studied in the Research Literature
Research on GLP-2 TRZ concentrates on receptor pharmacology, structural biology, and mechanistic studies in cells and rodent models. The entries below summarise areas investigators have studied and make no claims about outcomes.
Dual Receptor Agonism
The defining research theme is co-activation of the GIP and GLP-1 receptors by a single peptide. Pharmacological characterisation describes GLP-2 TRZ as an imbalanced, biased dual agonist in cell-based receptor assays.[2][6]
Structural Biology
Cryo-electron microscopy work has resolved how the peptide engages the GIP, GLP-1, and glucagon receptors, providing structural insight into its multiplexed binding at the molecular level.[3]
GIP Receptor Contribution
Studies in genetically modified obese mice have probed the weight-independent, GIP-receptor-mediated component of GLP-2 TRZ signalling on insulin sensitivity in animal models.[4]
Incretin Pathway Crosstalk
Reviews examine how GIP signalling may complement GLP-1 receptor activation, an area of mechanistic interest underpinning dual-agonist design.[5]
Beta-Cell & Insulin Signalling (Preclinical)
Mechanistic work has characterised effects of dual incretin-receptor engagement on beta-cell function and insulin signalling pathways in cell and animal systems.[1]
Peptide Engineering
The discovery paper details the molecular design, including the fatty-diacid side chain enabling reversible albumin binding studied in vitro as a persistence strategy.[1]
Reconstitution, Handling & Storage (Research)
These notes reflect general laboratory practice for lyophilised research peptides. They are procedural bench notes only and are not directions for use in any organism.
Reconstitution
Lyophilised peptide is commonly dissolved by adding sterile or bacteriostatic water slowly along the vial wall, then allowing it to dissolve gently without vortexing to minimise shear.
Aliquoting
Splitting reconstituted stock into single-use aliquots is a common laboratory practice to avoid repeated freeze-thaw cycles in multi-day studies.
Storage
Lyophilised material is typically held frozen and protected from light and humidity; reconstituted solutions are generally refrigerated and used within a short window per protocol.
Documentation
Logging lot number, concentration, solvent, and date of preparation supports reproducibility and traceability at the bench.
Stability & Half-Life Notes
As an acylated, albumin-binding peptide, GLP-2 TRZ is described in the engineering literature as more resistant to enzymatic degradation than native incretin hormones, with the side-chain design supporting extended molecular persistence in pharmacokinetic models.[1] The stability of any individual research preparation depends on solvent, pH, temperature, and freeze-thaw history; investigators should verify integrity for their own experimental conditions.
Research Use Only — Not For Human Use
GLP-2 TRZ supplied by Banger Labs is a research chemical intended exclusively for in-vitro and laboratory research by qualified professionals. It is not a medicine, has not been approved in this form for the diagnosis, treatment, cure, or prevention of any condition, and must not be administered to humans or animals. Nothing here describes therapeutic effect, dosing, or efficacy.
References
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018. PMID: 30473097
- Willard FS, Douros JD, Gabe MBN, et al. GLP-2 TRZ is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020. PMID: 32730231
- Zhao F, Zhou Q, Cong Z, et al. Structural insights into multiplexed pharmacological actions of GLP-2 TRZ and peptide 20 at the GIP, GLP-1 or glucagon receptors. Nat Commun. 2022. PMID: 35217653
- Samms RJ, Christe ME, Collins KAL, et al. GIPR agonism mediates weight-independent insulin sensitization by GLP-2 TRZ in obese mice. J Clin Invest. 2021. PMID: 34003802
- Samms RJ, Coghlan MP, Sloop KW. How May GIP Enhance the Therapeutic Efficacy of GLP-1? Trends Endocrinol Metab. 2020. PMID: 32396843
- Yuliantie E, Darbalaei S, Dai A, et al. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors. Biochem Pharmacol. 2020. PMID: 32360365
Scientific References
Explore the published research literature on GLP-2 TRZ. We link directly to independent, primary sources — we don't summarize or interpret findings. For research use only.
Links open external databases (pubmed.ncbi.nlm.nih.gov · clinicaltrials.gov). Banger Labs is not affiliated with these sources. For research use only — not medical advice.
Certificate of Analysis
GLP-2 TRZ · ≥99.4% purity (HPLC)